International Progressive MS Alliance e-News - March 2021 In this issue: • Read about the recent call to action to prioritise research on symptoms that matter most to people affected…read more
The Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) forum was held virtually in February this year. The Neurology Research Review have selected and reviewed 10 presentations.read more
Special issue of Neurology Research Review, focusing specifically on MS.read more
The projects cover a wide range of topics and research areas, including research into COVID-19 in people with MS in Australia.read more
This article, written by the Journal of Multiple Sclerosis and related disorders, (MSARD) includes data from clinical trials, post marketing safety surveillance and a US electronic medical records database, Optum.read more
New data on the long term benefits of Ocrelizumab for PPMS has recently been published 29 October 2020 on the Lancet Ocrelizumab is currently funded for RRMS in New Zealand…read more
Keep up with the latest researching on COVID-19 as it relates to Multiple Sclerosisread more
Exploring patterns of medicinal cannabis use prior to implementation of the new Medicinal Cannabis Scheme (MCS) in New Zealand.read more
Positive psychological health and self-compassion are important for positive outcomes for people with MS and protect them against poorer outcomes.read more
Time matters in multiple sclerosis (MS). Irreversible neural damage and cell loss occur from disease onsetread more
Research findingsread more
This short guide is a resource to help people with multiple sclerosis (MS) understand how they can keep their brains as healthy as possible and request the highest possible standard…read more
Policy initiative to stimulate debate about advocating a treatment approach in multiple sclerosis that aims to minimize disease activity and maximize lifelong ‘brain health’read more
A team of researchers has published results from a small, five-year study of transplantation of individuals’ own hematopoietic (blood cell-producing) stem cells combined with high-dose immunotherapy in 24 people with…read more
